Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (330)	4/28/2005 3:46:59 PM
From: tuck	Respond to of 510

[SELDI for liver cancer] >>Zhonghua Yi Xue Za Zhi. 2005 Jan;85(3):189-192. [Using ANN and Serum Protein pattern models in liver Cancer Diagnosis.] [Article in Chinese] Wang JX, Zhang B, Yu JK, Liu J, Yang MQ, Zheng S. Zhejiang University Cancer Institute, Hangzhou 310000, China. OBJECTIVE: To set up a method for the detection of the serum protein fingerprint pattern by using the protein chip technology for exploration of serum protein fingerprint pattern models based on the artificial neural network in diagnosis of liver cancer. METHODS: One hundred and six serum samples form subjects with liver cancer, hepatocirrhosis, and healthy individuals were detected with protein biochip surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) for protein fingerprint pattern, and analyzed with the artificial neural network. The 106 samples were randomly put into a training group (n = 70, 35 patients with liver cancer, 14 patients with hepatocirrhosis, and 21 healthy individuals) and a blind test group (n = 36, 17 patients with liver cancer, 8 patients with hepatocirrhosis, and 11 healthy individuals). RESULTS: The serum protein fingerprint pattern model obtained by the artificial neural network from training group was used to detect the 36 unknown serum samples. The sensitivity and specificity of this method in detection of liver cancer were 88.2% (15/17) and 94.6% (18/19) respectively. CONCLUSION: In comparison with the traditional methods, this new method has higher sensitivity and specificity in diagnosis of liver cancer and should be further studied.<< Not the same folks who did the 3 year study presented at AACR. No mention of sample prep or calibration protocols. Cheers, Tuck